Home » Newsletters » BioWorld Asia

BioWorld Asia

June 2, 1999

View Archived Issues

Cortecs' Macritonin Fails; Stock Drops One-Fourth

Dolly's Shorter Telomeres Mean Brief Culture Time Best In Therapy Research

RPR's p53 Gene Therapy Strong In Phase II Trials

CGL's Surface-Protein Work Boosted By #4M Financing

Genset, Alghne Sign Deal For Alzheimer's Research

AnorMED's HIV Treatment Moves Into Phase II Study

Thallia Plans Launch Of Circulatory Product

CAT Ending Program For Obesity Antibody

Appligene Oncor Says Sales Up, Losses Lower

Oxagen, Lynx Partnering In Disease-Linked SNPs

Cerep Reports Revenues, Enters Deal With Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...